Choline kinase inhibition and docking studies of a series of 6-(benzylthio)-9H-purin-9-yl-pyridinium derivatives
Human choline kinase is a well validated target for the treatment of cancer. In the last two decades, many choline kinase inhibitors have been developed and one of them is currently under evaluation in clinical trials. In this paper a series of 6-(benzylthio)-9H-purin-9-yl-pyridinium derivatives were evaluated as choline kinase inhibitors, and their effects on cell proliferation were also investigated in the human hepatoma HepG2 cell line. The most potent inhibitor against purified choline kinase-α1 presents an IC50 value of 0.4 μM. The biological data and the docking studies described here, support that the 4-(dimethylamino)pyridinium cationic head and a small linker (benzene or biphenyl) are the essential structural parameters for choline kinase inhibition of the tested compounds.
KeywordsCholine kinase Inhibitors Pyridinium compounds Antiproliferative agents Lipophilicity
We thank the ‘Consejería de Innovación, Ciencia y Empresa, Junta de Andalucía’ (Excellence Research Project no. P07-CTS-03210) and the ‘Ministerio de Ciencia e Innovación’ (Project no. SAF2009-11955) for the financial support. The award of grants from the ‘Ministerio de Educación’ to B.R.-R. and P.R.-M. is gratefully acknowledged.
Conflicts of Interest
The authors declare that they have no competing interests.
- Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC (2009) Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS ONE 4:e7819CrossRefPubMedPubMedCentralGoogle Scholar
- Gaussian Inc. (2004) Wallingford, CT http://www.gaussian.com
- Granata A, Nicoletti R, Perego P, Iorio E, Krishnamachary B, Benigni F, Ricci A, Podo F, Bhujwalla ZM, Canevari S, Bagnoli M, Mezzanzanica D (2015) Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget 6:11216–11230CrossRefPubMedPubMedCentralGoogle Scholar
- Rubio-Ruiz B, Ramos-Torrecillas J, Capitán-Cañadas F, Sánchez-Martín RM, Gallo MA, Espinosa A, Ruiz C, Conejo-García A, Entrena A (2013a) Antiproliferative activity, cell cycle, and apoptosis studies of a series of 6-substituted 9H-purin-9-yl-pyridinium derivatives on a human cervical carcinoma cell line. ChemMedChem 8:1266–1269CrossRefPubMedGoogle Scholar
- Sahún-Roncero M, Rubio-Ruiz B, Saladino G, Conejo-García A, Espinosa A, Velázquez-Campoy A, Gervasio FL, Entrena A, Hurtado-Guerrero R (2013b) The mechanism of allosteric coupling in choline kinase α1 revealed by the action of a rationally designed inhibitor. Angew Chem Int Ed 52:4582–4586CrossRefGoogle Scholar
- SYBYL-X 2.0, Tripos International, St. Louis, Missouri, USA. http://www.tripos.com
- The PyMOL Molecular Graphics System, Version 1.4, Schrödinger, LLCGoogle Scholar
- Zech SG, Kohlmann A, Zhou T, Li F, Squillace RM, Parillon LE, Greenfield MT, Miller DP, Qi J, Thomas RM, Wang Y, Xu Y, Miret JJ, Shakespeare WC, Zhu X, Dalgarno DC (2016) Novel small molecule inhibitors of choline kinase identified by fragment-based drug discovery. J Med Chem 59:671–686CrossRefPubMedGoogle Scholar